128 related articles for article (PubMed ID: 28692456)
21. Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data.
Hopkins AM; Van Dyk M; Rowland A; Sorich MJ
Pigment Cell Melanoma Res; 2019 Jul; 32(4):576-583. PubMed ID: 30758912
[TBL] [Abstract][Full Text] [Related]
22. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy.
Chen FW; Tseng D; Reddy S; Daud AI; Swetter SM
JAMA Dermatol; 2014 Nov; 150(11):1209-12. PubMed ID: 25142409
[TBL] [Abstract][Full Text] [Related]
23. Cobimetinib (Cotellic) for metastatic melanoma.
Med Lett Drugs Ther; 2016 Mar; 58(1491):43-4. PubMed ID: 27027689
[No Abstract] [Full Text] [Related]
24. MEK inhibitor-induced dusky erythema: characteristic drug hypersensitivity manifestation in 3 patients.
Patel U; Cornelius L; Anadkat MJ
JAMA Dermatol; 2015 Jan; 151(1):78-81. PubMed ID: 25426865
[TBL] [Abstract][Full Text] [Related]
25. The relative clinical efficacy of trametinib-dabrafenib and cobimetinib-vemurafenib in advanced melanoma: an indirect comparison.
Galván-Banqueri M; Ubago-Pérez R; Molina-López T
J Clin Pharm Ther; 2016 Jun; 41(3):285-9. PubMed ID: 27079278
[TBL] [Abstract][Full Text] [Related]
26. Recurrent Central Serous Chorioretinopathy Under Combined Vemurafenib and Cobimetinib Treatment.
Kouros P; Gerding H
Klin Monbl Augenheilkd; 2016 Apr; 233(4):488-9. PubMed ID: 27116515
[No Abstract] [Full Text] [Related]
27. Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells.
Singh A; Ruan Y; Tippett T; Narendran A
J Exp Clin Cancer Res; 2015 Sep; 34(1):104. PubMed ID: 26384788
[TBL] [Abstract][Full Text] [Related]
28. Atypical systemic sarcoid-like granulomatosis in two patients treated with BRAF and MEK inhibitors.
Assan F; Schlemmer F; Assie JB; Mahevas M; Sustronck P; Ortonne N; Velter C; Fardet L; Zehou O
Eur J Dermatol; 2019 Oct; 29(5):556-557. PubMed ID: 31649010
[No Abstract] [Full Text] [Related]
29. BRAF and MEK inhibition in melanoma.
Dossett LA; Kudchadkar RR; Zager JS
Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
[TBL] [Abstract][Full Text] [Related]
30. MEK Retinopathy. Clinical case reports.
Rocha Cabrera P; Quijada Fumero E; Losada Castillo MJ; Abreu Reyes JA; Lorenzo Morales J
Arch Soc Esp Oftalmol (Engl Ed); 2018 Jan; 93(1):42-46. PubMed ID: 28506716
[TBL] [Abstract][Full Text] [Related]
31. The role of MEK inhibitors in the treatment of metastatic melanoma.
Grimaldi AM; Simeone E; Ascierto PA
Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
[TBL] [Abstract][Full Text] [Related]
32. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
[TBL] [Abstract][Full Text] [Related]
33. Severe gastrointestinal toxicity of MEK inhibitors.
Mourad N; Lourenço N; Delyon J; Eftekhari P; Bertheau P; Allayous C; Ballon A; Pagès C; Allez M; Lebbé C; Baroudjian B;
Melanoma Res; 2019 Oct; 29(5):556-559. PubMed ID: 31095035
[TBL] [Abstract][Full Text] [Related]
34. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
[TBL] [Abstract][Full Text] [Related]
35. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy.
Tran KA; Cheng MY; Mitra A; Ogawa H; Shi VY; Olney LP; Kloxin AM; Maverakis E
Drug Des Devel Ther; 2016; 10():43-52. PubMed ID: 26730180
[TBL] [Abstract][Full Text] [Related]
36. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.
Mey UJM; Renner C; von Moos R
Hematol Oncol; 2017 Dec; 35(4):890-893. PubMed ID: 27641727
[TBL] [Abstract][Full Text] [Related]
37. Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics.
Cheeti S; Deng Y; Chang I; Georgescu I; Templeton I; Choong N; Cheung KWK; Girish S; Musib L
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):144-152. PubMed ID: 32696585
[TBL] [Abstract][Full Text] [Related]
38. The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes.
Lulli D; Carbone ML; Pastore S
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29064427
[TBL] [Abstract][Full Text] [Related]
39. Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma.
Lamiaux M; Scalbert C; Lepesant P; Desmedt E; Templier C; Dziwniel V; Staumont-Sallé D; Mortier L
Melanoma Res; 2018 Oct; 28(5):451-457. PubMed ID: 29985833
[TBL] [Abstract][Full Text] [Related]
40. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.
Choo EF; Ly J; Chan J; Shahidi-Latham SK; Messick K; Plise E; Quiason CM; Yang L
Mol Pharm; 2014 Nov; 11(11):4199-207. PubMed ID: 25243894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
